Home › Funds › NAN FUNG TRINITY (HK) Ltd › BCRX

NAN FUNG TRINITY (HK) Ltd position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

NAN FUNG TRINITY (HK) Ltd reported holding 938,200 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$7.8M, representing 0.75% of its reported portfolio and ranking #45 among its reported holdings. NAN FUNG TRINITY (HK) Ltd has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)938.20K sh
Reported value held$7.82M
Portfolio Weight0.75%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How NAN FUNG TRINITY (HK) Ltd's BCRX position evolved

NAN FUNG TRINITY (HK) Ltd first disclosed a stake in BCRX in Q2 2026 at 450,000 shares (US$4.5M). The position peaked in Q3 2026 at 938,200 shares, worth US$7.8M. Across 2 filings, NAN FUNG TRINITY (HK) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 938,200 shares valued at US$7.8M — an increase of 488,200 shares quarter over quarter.. Notable position changes include a 108% increase in Q3 2026 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 450.00K $4.50M New
Q3 2026 938.20K $7.82M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has NAN FUNG TRINITY (HK) Ltd held BCRX?

NAN FUNG TRINITY (HK) Ltd has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is NAN FUNG TRINITY (HK) Ltd's current position in BCRX?

As of Q3 2026, NAN FUNG TRINITY (HK) Ltd holds 938.20K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $7.82M, representing 0.75% of its reported portfolio and ranking #45.

Has NAN FUNG TRINITY (HK) Ltd been buying or selling BCRX?

In the latest 13F filing (Q3 2026), NAN FUNG TRINITY (HK) Ltd increased its position in BCRX. The position peaked in Q3 2026 at 938.20K shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.